SPRY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ARS Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means ARS Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .
ARS Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means ARS Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
ARS Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ARS Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $219.92 Mil.
The historical data trend for ARS Pharmaceuticals's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Change In Receivables | - | - | - | - |
ARS Pharmaceuticals Quarterly Data | ||||||||||||
Dec20 | Jun21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals (NAS:SPRY) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
ARS Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, ARS Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:
ARS Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 223.632 | - | 3.715 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 219.92 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of ARS Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander A Fitzpatrick | officer: Chief Legal Officer | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Laura Shawver | director, officer: Chief Executive Officer | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Capital Gp Vi Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Capital Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Brian Dorsey | officer: Chief Operating Officer | C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130 |
Kathleen D. Scott | officer: Chief Financial Officer | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Pratik Shah | director, 10 percent owner | 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037 |
Jonathan S Leff | director | C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Private Design Fund Iv, L.p. | director, 10 percent owner, other: * Director by deputization | 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Mgmt Iv, L.p. | director, 10 percent owner, other: * Director by deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Ra Capital Nexus Fund Ii, L.p. | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Brent L Saunders | director | 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033 |
From GuruFocus
By Marketwired • 10-02-2023
By Marketwired • 10-16-2023
By Marketwired • 10-05-2023
By GuruFocus Research • 10-03-2023
By Marketwired • 10-20-2023
By Marketwired • 09-28-2023
By sperokesalga sperokesalga • 06-18-2023
By PRNewswire PRNewswire • 05-19-2023
By sperokesalga sperokesalga • 05-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.